Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sunshine Biopharma Inc.SBFM · Entity 8329 | CFO/Secretary | November 30, 2022 | December 02, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sunshine Biopharma Inc.
Report date November 30, 2022 · Filed December 02, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 174,465 |
Reported balance
After 2022-11-30 transaction · row 1
1 source rowRow 1 · 2022-11-30 · Purchase · Acquired 30,000 · Balance 174,465 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 30, 2022 Filed Dec 2, 2022 06:01 UTC | Sunshine Biopharma Inc. SBFM · Entity 8329 | PurchaseCommon Stock | 30,000 | $0.76 | $22,905.00 |
DisclosureSEC source: 0001683168-22-008144 · ownership.xml · nonDerivative · entry 1 Sebaaly Camille · CIK 0001474695 · CFO/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,465 Read SEC document |
| June 03, 2022 Filed Jun 6, 2022 12:36 UTC | Sunshine Biopharma Inc. SBFM · Entity 8329 | PurchaseCommon Stock | 25,000 | $1.22 | $30,500.00 |
DisclosureSEC source: 0001683168-22-004178 · ownership.xml · nonDerivative · entry 1 Sebaaly Camille · CIK 0001474695 · CFO/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,465 Read SEC document |
| January 06, 2021 Filed Feb 16, 2021 12:23 UTC | Sunshine Biopharma Inc. SBFM · Entity 8329 | GrantCommon Stock | 20,000,000 | $0.00 | $20,000.00 |
DisclosureSEC source: 0001128732-21-000001 · primary_doc.xml · nonDerivative · entry 1 Sebaaly Camille · CIK 0001474695 · Director · CFO/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,893,086 Read SEC document |
| December 31, 2019 Filed Jul 15, 2020 12:09 UTC | Sunshine Biopharma Inc. SBFM · Entity 8329 | GrantCommon Stock | 323,673 | $0.00 | $323.67 |
DisclosureSEC source: 0001128732-20-000005 · primary_doc.xml · nonDerivative · entry 4 Sebaaly Camille · CIK 0001474695 · Director · CFO/Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · Held by TRT Pharma Inc. Disclosed balance after: 0 F1 · shares: The amount of Securities Acquired or Disposed of and Securities Beneficially Owned reported herein are post the effectiveness of a February 1, 2019 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person and post the effectiveness of an April 6, 2020 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person. F1 · balance_after: The amount of Securities Acquired or Disposed of and Securities Beneficially Owned reported herein are post the effectiveness of a February 1, 2019 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person and post the effectiveness of an April 6, 2020 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person. F3 · ownership.nature: Effective December 31, 2019, 4019318 Canada, Inc., an entity controlled by the Reporting Person, effectuated a consolidation with Advanomics Corporation, an entity controlled by the Chief Executive Officer of the Issuer. The resulting consolidated entity changed its name to TRT Pharma Inc. The consolidation resulted in the transfer of 323,673 shares of post-reverse splits of the Issuer's Common Stock to TRT Pharma Inc. and the Reporting Person no longer being a control person of TRT Pharma Inc. Read SEC document |
| December 19, 2019 Filed Jul 15, 2020 12:09 UTC | Sunshine Biopharma Inc. SBFM · Entity 8329 | GrantCommon Stock | 1,300,000 | $0.00 | $1,300.00 |
DisclosureSEC source: 0001128732-20-000005 · primary_doc.xml · nonDerivative · entry 3 Sebaaly Camille · CIK 0001474695 · Director · CFO/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,893,086 F1 · shares: The amount of Securities Acquired or Disposed of and Securities Beneficially Owned reported herein are post the effectiveness of a February 1, 2019 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person and post the effectiveness of an April 6, 2020 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person. F1 · balance_after: The amount of Securities Acquired or Disposed of and Securities Beneficially Owned reported herein are post the effectiveness of a February 1, 2019 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person and post the effectiveness of an April 6, 2020 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person. Read SEC document |
| October 20, 2019 Filed Jul 15, 2020 12:09 UTC | Sunshine Biopharma Inc. SBFM · Entity 8329 | GrantCommon Stock | 1,100,000 | $0.00 | $1,100.00 |
DisclosureSEC source: 0001128732-20-000005 · primary_doc.xml · nonDerivative · entry 2 Sebaaly Camille · CIK 0001474695 · Director · CFO/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,593,086 F1 · shares: The amount of Securities Acquired or Disposed of and Securities Beneficially Owned reported herein are post the effectiveness of a February 1, 2019 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person and post the effectiveness of an April 6, 2020 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person. F1 · balance_after: The amount of Securities Acquired or Disposed of and Securities Beneficially Owned reported herein are post the effectiveness of a February 1, 2019 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person and post the effectiveness of an April 6, 2020 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person. Read SEC document |
| September 11, 2019 Filed Sep 23, 2019 09:56 UTC | Sunshine Biopharma Inc. SBFM · Entity 8329 | GrantCommon Stock | 11,000,000 | $0.00 | $11,000.00 |
DisclosureSEC source: 0001128732-19-000025 · primary_doc.xml · nonDerivative · entry 2 Sebaaly Camille · CIK 0001474695 · Director · Secretary · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,861,719 Read SEC document |
| September 11, 2019 Filed Jul 15, 2020 12:09 UTC | Sunshine Biopharma Inc. SBFM · Entity 8329 | GrantCommon Stock | 550,000 | $0.00 | $550.00 |
DisclosureSEC source: 0001128732-20-000005 · primary_doc.xml · nonDerivative · entry 1 Sebaaly Camille · CIK 0001474695 · Director · CFO/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,493,086 F1 · shares: The amount of Securities Acquired or Disposed of and Securities Beneficially Owned reported herein are post the effectiveness of a February 1, 2019 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person and post the effectiveness of an April 6, 2020 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person. F2 · shares: Shares issued by the Issuer to the Reporting Person for consulting services provided to the Issuer. F1 · balance_after: The amount of Securities Acquired or Disposed of and Securities Beneficially Owned reported herein are post the effectiveness of a February 1, 2019 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person and post the effectiveness of an April 6, 2020 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person. Read SEC document |
| September 02, 2019 Filed Sep 23, 2019 09:56 UTC | Sunshine Biopharma Inc. SBFM · Entity 8329 | GrantCommon Stock | 13,000,000 | $0.00 | $13,000.00 |
DisclosureSEC source: 0001128732-19-000025 · primary_doc.xml · nonDerivative · entry 1 Sebaaly Camille · CIK 0001474695 · Director · Secretary · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,861,719 F1 · balance_after: Effective February 1, 2019, Issuer effectuated a reverse stock split wherein 1 share of Common Stock was issued for each 20 shares of the issued and outstanding Common Stock of the Issuer resulting in Reporting Person owning 5,861,719 shares of Common Stock of the Issuer as of that date. Read SEC document |
| August 27, 2018 Filed Sep 14, 2018 10:14 UTC | Sunshine Biopharma Inc. SBFM · Entity 8329 | GrantCommon Stock | 38,000,000 | $0.00 | $38,000.00 |
DisclosureSEC source: 0001128732-18-000012 · primary_doc.xml · nonDerivative · entry 1 Sebaaly Camille · CIK 0001474695 · Director · Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,234,373 Read SEC document |
| June 20, 2018 Filed Jun 28, 2018 17:52 UTC | Sunshine Biopharma Inc. SBFM · Entity 8329 | GrantCommon Stock | 27,000,000 | $0.00 | $27,000.00 |
DisclosureSEC source: 0001128732-18-000007 · primary_doc.xml · nonDerivative · entry 1 Sebaaly Camille · CIK 0001474695 · Director · Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,234,373 Read SEC document |
| July 20, 2017 Filed Sep 8, 2017 09:45 UTC | Sunshine Biopharma Inc. SBFM · Entity 8329 | GrantCommon Stock | 14,000,000 | $0.00 | $14,000.00 |
DisclosureSEC source: 0001128732-17-000032 · primary_doc.xml · nonDerivative · entry 1 Sebaaly Camille · CIK 0001474695 · Director · Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,234,373 Read SEC document |
| December 06, 2016 Filed Dec 15, 2016 19:50 UTC | Sunshine Biopharma Inc. SBFM · Entity 8329 | GrantCommon Stock | 26,000,000 | $0.00 | $26,000.00 |
DisclosureSEC source: 0001128732-16-000037 · primary_doc.xml · nonDerivative · entry 1 Sebaaly Camille · CIK 0001474695 · Director · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,234,373 Read SEC document |
| October 10, 2016 Filed Nov 7, 2016 12:01 UTC | Sunshine Biopharma Inc. SBFM · Entity 8329 | OtherCommon Stock | 129,468,927 | $0.00 | $0.00 |
DisclosureSEC source: 0001128732-16-000031 · primary_doc.xml · nonDerivative · entry 1 Sebaaly Camille · CIK 0001474695 · Director · CFO and Secretary · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Owned by 4019318 Canada Inc., an entity controlled by Reporting Person. Disclosed balance after: 129,468,927 F1 · kind: 129,468,927 shares were acquired by 4019318 Canada Inc., an entity controlled by Reporting Person, pursuant to a share exchange with an unrelated entity; no consideration was paid as a result of the share exchange. F1 · price: 129,468,927 shares were acquired by 4019318 Canada Inc., an entity controlled by Reporting Person, pursuant to a share exchange with an unrelated entity; no consideration was paid as a result of the share exchange. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.